KalVista Pharmaceuticals, Inc.
KALV$499M
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaFRAMINGHAM270 employees
Drugs in Pipeline
4
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
KALV News
Catalyst Timeline
0 upcoming, 2 past
No catalysts found.
Drug Pipeline
KVD900 300 mg
Hereditary Angioedema
KVD900 600 mg
Hereditary Angioedema
KVD001 Injection
Diabetic Macular Edema
KVD900
Hereditary Angioedema
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
KVD900 300 mg | Phase 3 | Hereditary Angioedema | - | - |
KVD900 600 mg | Phase 3 | Hereditary Angioedema | - | - |
KVD001 Injection | Phase 2 | Diabetic Macular Edema | - | - |
KVD900 | Phase 2 | Hereditary Angioedema | - | - |
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply